Single nucleotide polymorphism rs696 in miR449a binding site of NFKBIA gene is correlated with risk of colorectal cancer

Miganoosh Simonian1, Meysam Mosallayi1, Maryam Miraghajani2, Awat Feizi3, Sharifeh Khosravi1, Ahmad Reza Salehi1, Deniz Mortazavi1, Farideh Saberi1, Rasoul Salehi1,4,5
1Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
2Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
3Department of Biostatistics and Epidemiology, School of Health, Isfahan University of Medical Sciences, Isfahan, Iran.
4Acquired Immunodeficiency Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
5Gerfa Namayesh Azmayesh (GENAZMA) Science & Research Institute, Isfahan, Iran

ABSTRACT

Aim: In present study we have elucidated the role of 2758 A>G (rs696), in the recognition site of miR449a in the 3' UTR of NFKB inhibitor alpha (NFKBIA) gene, in development of sporadic colorectal cancer.

Background: Colorectal cancer (CRC) is rated as second cause of cancer death. Genetic determinants are considered as driving forces in development of sporadic CRC. Single nucleotide polymorphisms (SNPs), are attributed as the main genetic factor in cancers susceptibility. MicroRNAs, are key players in post-translational gene regulation by binding to their specific recognition sequences located at 3’ untranslated region (UTR) of mRNAs.

Methods: A case–control study using 143 CRC patients and 137 noncancerous counterparts were undertaken in order to determine rs696 genotypes using polymerase chain reaction– restriction fragment length polymorphism (PCR–RFLP) method.

Results: There was a significant difference for the genotype frequencies of rs696 between patients and controls. The frequencies of GG, AG, AA genotypes in the control group were 38.7, 45.3, and 16.1 %, respectively, and the genotype frequencies in case group were 19.6, 40.6, and 39.9 %, respectively.

Conclusion: Our results suggest significant correlation between rs696 polymorphism and colorectal cancer risk.

Keywords: NFKBIA gene, microRNA, single-nucleotide polymorphism, colorectal Cancer.

Introduction

Globally, more than one million people experience CRC every year, and it has become the third and second most common malignancy in men and women respectively (1, 2). Despite this fact that Iran is still a low risk country for CRC, based on the World Health Organization (WHO) reports, its incidence rate currently showing rapid increase perhaps due to the Westernization of lifestyle in Asia countries, including Iran (3, 4). Approximately 80% of all CRC cases are sporadic, indicating that besides genetic basis, environmental and lifestyle factors also play important roles. Alcohol, tobacco, type of diets, physical activity, nonsteroidal anti-inflammatory drugs (NSAIDs) usage and inflammatory bowel disease (IBD) are important risk factors for CRC development (5-7). There is a growing body of evidence that inflammatory microenvironment is an essential component of all cancers, especially colon tumors (8). Chronic inflammation is likely to be implicated in various forms of sporadic as well as heritable colon cancer (8). As a crucial inflammatory element nuclear factor kappa B (NFkB), could have an oncogenic role by promoting the growth and survival of many solid malignancies (9).
NFKB seems to be activated in wide fraction of tumors such as breast, colon, prostate and stomach and implicate to tumor progression and angiogenesis (10-13). Meanwhile IKBα, the inhibitor of NFKB, has been reported to be inactive or downregulated during various NFKB activation processes (14). NFKB/IκBa complex is a central hub in networked cellular transcriptional responses; with wide impact on expression of different genes. Its dysregulation contributes to important cellular phenomenon like angiogenesis, cell proliferation, invasion and anti-apoptosis processes favoring oncogenesis (15).

MicroRNAs (miRNAs), small noncoding RNA molecules with ~22 nucleotides, have attracted great attentions because of their principle role in various aspects of cellular biology such as cell differentiation, proliferation, cell cycle progression and apoptosis (16, 17). miRNAs could affect the level of mRNA expression through hybridization to complementary sequences in the 3' untranslated region (UTR) of the target gene transcripts (18). Recent studies have indicated that single nucleotide polymorphisms (SNPs) in miRNA binding sites could modulate miRNA-mRNA interactions and change gene expression drastically by either creating new or deleting existing miRNAs binding sites (19).

In silico analyses it was indicated that NFKBIA 2758 A>G (rs696) variant located at recognition site of miR449a (20). Moreover Song et al. (20) ex vivo luciferase data manifested that 2758 A allele thermodynamically favor stronger binding capacity of miR-449a with 3'UTR of NFKBIA, which result in decreased expression of NFKBIA and in turn constitutive activity of NFKB. Therefore, individuals carrying AA genotype at rs696 lesser amount of NFKB inhibitor and unchecked NFKB remain with prolonged activity which is in favor of infectious and inflammatory diseases as well as tumorigenesis (21). Environmental factors like NSAID use, smoking, physical activity in relation with rs696 genotypes and their influence on colorectal cancer susceptibility was also worked out. Given that NFKBIA polymorphisms have not studied yet in Iranian population. The aim of our study was to examine the risk associated with variants of rs696 located in 3’ UTR of NFKBIA gene among a group of Iranian patients diagnosed with sporadic CRC.

**Methods**

**Study population and sample preparation**

A total of 143 patients with histologically confirmed colorectal cancer and no familial history of related cancers were enrolled for this study. Patients were recruited from colonoscopy units of Alzahra and Syedolshohada hospitals between June 23, 2013 and July 15, 2015. Hundred and thirty seven individuals with no evidence of colonoscopy signs of CRC were randomly selected from the same residential areas, during the same period of time. This study was approved by the university ethics committee and all participants provided the written informed consent. The study participants were interviewed and data on gender, age, smoking status, NSAID usage, physical activity and other factors including family history of cancers were obtained using a structured questionnaire. All mandatory applicable laboratory health and safety procedures related to this research have been fully observed and practiced.

**DNA extraction and NFKBIA genotyping**

Genomic DNA was extracted from 5ml EDTA-anticoagulated peripheral blood samples by Prime Prep Genomic DNA Isolation Kit (GeNetBio, Korea). DNA was stored at -20°C until analyzed. The quality and quantity of the extracted DNA was assessed by agarose gel electrophoresis and spectroscopy. The polymerase chain reaction fragment length polymorphism (PCR-RFLP) method was used to determine rs696 genotypes. PCR was performed in a total 25µl volume containing,
2.5 µl 10x PCR buffer, 1.5 mM MgCl2, 200 µM dNTPs, 0.2µM each primer, 100 ng of genomic DNA, and 1 U of Taq DNA polymerase. Thermal cycling profile adjusted at 94°C for 5 min followed by 34 cycles of 94°C, 64°C and 72°C all for 30 seconds with a final extension step of 72°C for 5 min. Primer sequences, reaction conditions, and restriction enzyme used are given in Table 1. The PCR products were digested with HaeIII restriction endonuclease enzyme overnight at 37°C. Subsequently restriction enzyme was inactivated at 80°C for 20 minutes and then analyzed on 2% agarose gel. Fragment sizes of 535 and 410 bp were indicative of AG heterozygous genotype; a single 410 bp fragment displayed the presence of GG homozygous and one fragment of 535 bp indicated AA genotype (Figure 1). To confirm RFLP genotyping results some of the samples were randomly selected and subjected to direct sequencing.

Statistical analyses

All data analyses were carried out using SPSS 22.0 statistical software. The t-test and the Chi-squared (χ²) test were used to compare the differences of demographic characteristics distributions between CRC patients and the control group. Hardy–Weinberg equilibrium was tested among cases and controls using Pearson’s Chi square test. Genotype and allele frequency differences between cases and controls were evaluated using logistic regression analysis, with odds ratios (OR) and 95% confidence intervals (95% CI). \( P \) value < 0.05 was considered statistically significant.

Results

Our study population consisted of 143 CRC patients (75 males and 68 females) and 137 CRC free individuals (54 males and 83 females). The distributions of selected characteristics of the cases and controls are presented in Table 2. There were no statistically significant differences between patients and controls in terms of BMI and smoking status (\( P = 0.10 \) and \( P = 0.34 \) respectively). However, we found a significant difference in physical activity (\( P = 0.007 \)) between case and control groups. Also individuals in control group were more aspirin or NSAID users compared with sporadic CRC cases (\( P < 0.004 \)). The case group had a higher proportion of male subjects (52.4% vs 39.4%).

Genotyping data were in Hardy–Weinberg equilibrium for this SNP in the tested groups. There was a significant difference for the genotype frequencies of rs696 between patients and controls. The frequencies of GG, AG, AA genotypes in the control group were 38.7, 45.3, and 16.1 %, respectively, and the genotype frequencies in case group were 19.6, 40.6, and 39.9 %, respectively. This result demonstrated the significant association of AA genotype with risk of CRC in our study population (adjusted OR= 3.46; 95%CI [1.96–6.10]; \( P < 0.001 \)). In allele distribution analysis we found increased level of allele A in cases, compared with controls. This allele was associated with an increased risk of CRC (adjusted OR= 2.39; CI [1.70–3.35]; \( P < 0.001 \)). The distributions of genotype and allele frequency are shown in Table 3.

As mentioned above we also found that our case group consumed less aspirin or NSAID compared to control group (73.7 vs. 87.4 %, \( P = 0.004 \)). The analysis for correlation between NFKBIA genotypes and NSAIDs consumption demonstrated that in drug user patients, AA genotype was more frequent vs. AG, GG genotype (61.1% vs. 19.4%, \( P = 0.002 \)). While in control group, the situation was reverse (38.9% vs. 80.6%). Data are shown in Table 4.
In the present study, we found that the genetic variant, rs696 A>G of the NFKBIA gene significantly correlates with colon cancer in Iranian population. Analysis indicated that homozygous AA genotype (adjusted OR = 3.46; 95% CI [1.96–6.10]) was more frequent in CRC patients. Also individuals possessing allele A were more frequently affected with CRC than those with G allele (adjusted OR = 2.39; CI [1.70–3.35]).

In a study conducted in China AA genotype of rs696 polymorphism found to be correlated with elevated risk of nasopharyngeal carcinoma (22). Such association has also been confirmed with Behçet’s disease and lung cancer in Turkish and Chinese populations respectively (23, 24). AA variant involvement in increased risk of aforementioned malignancies must be due to the downregulation of IkBα expression because of the modulation of miR-449a binding site on 3’UTR of the gene. On the other hand, the correlation of GG genotype with an increased risk for extensive colitis in Hungarian patients is inconsistent with the above mentioned findings. Also subjects with GG genotype determined to be at twofold higher risk of cervical cancer as compare to controls (25). Curran et al. (26) could not find correlation of this SNP with susceptibility to sporadic breast cancer in Caucasian population. Moreover, Geo et al. (27) indicated that in Chinese population AG genotype was more in CRC patient with ≥50 years, while GG genotype considered as prognostic factor in Swedish CRC patients.

### Table 2. Baseline characteristics of CRC patients and controls in study

|                      | Controls (N: 137) | Cases (N: 143) | P value |
|----------------------|-------------------|----------------|---------|
| **Age (mean ± SD)**  | 55.77±13.25       | 56.60±10.33    | 0.56    |
| **gender**           |                   |                |         |
| male                 | 54(39.4%)         | 75(52.4%)      | 0.02*   |
| female               | 83(60.6%)         | 68(47.6%)      |         |
| **smoking**          |                   |                |         |
| Yes                  | 21(15.3%)         | 28(19.6%)      | 0.34    |
| No                   | 116(84.7%)        | 115(80.4)      |         |
| **NSAIDs**           |                   |                |         |
| irregular            | 101(73.7%)        | 125(87.4%)     | 0.004*  |
| regular              | 36(26.3%)         | 18(12.6%)      |         |
| **Physical activity**|                   |                |         |
| low                  | 82(59.9%)         | 108(75.5%)     | 0.007*  |
| moderate             | 34(24.8%)         | 27(18.9%)      |         |
| high                 | 21(15.3%)         | 8(5.6%)        |         |
| **BMI (mean ± SD) kg/m2** |            |                |         |
|                      | 25.82±4.03        | 27.33±7.77     | 0.10    |

* P value < 0.05

### Table 3. Association between genotypes and allele frequency with CRC risk

|                      | Case No (%) | Control No (%) | P value | OR (95% CI)       |
|----------------------|-------------|----------------|---------|-------------------|
| **Genotype frequency** |             |                |         |                   |
| GG                   | 28(19.6%)   | 53(38.7%)      | <0.001* | 3.46 (1.96–6.10)  |
| AG                   | 58(40.6%)   | 62(45.3%)      |         |                   |
| AA                   | 57(39.9%)   | 22(16.1%)      |         |                   |
| **Allele frequency**  |             |                |         |                   |
| G                    | 114 (39.9%) | 168(61.3%)     | <0.001* | 2.39(1.70-3.35)   |
| A                    | 172(60.1%)  | 106(38.7%)     |         |                   |

* P value < 0.05

### Table 4. Association of NSAIDs consumption with genotype

| Group                | Genotype | P value | OR (95% CI)       |
|----------------------|----------|---------|-------------------|
| **regular NSAIDs Consuming** |          |         |                   |
| Case                 | GG+AG    | 0.002*  | 6.51 (1.85-22.87) |
| Control              |          |         |                   |
|                      | GG+AG    | 29(80.6%)| 7(38.9%)          |

* P value < 0.05
52 NFKBIA 3′ UTR AG (rs696) polymorphism and risk of CRC

together, these contradictory results suggest that the
correlation of this polymorphism with cancers might
vary among various populations due to differences in
ethnic background and different types of cancers and
highlight the importance of population based studies
more than before.

To examine the interaction between the NFKBIA
genotypes and NSAID use, we assessed the effect of
NSAID use stratified by NFKBIA genotypes in drug
user subgroup. The result showed that patients with AA
genotype of this polymorphism appeared to have less
benefit of NSAID use; it is plausible that NSAID use
could affect by NFKBIA genotypes. Without doubt,
agents such as NSAIDS that inhibit inflammatory
events can reduce the risk of CRC. Based on the
available reports 50% diminution in the incidence of
colorectal cancer attributed to the regular aspirin users
(28, 29). But our data may lead to this conclusion that
all individuals consuming NSAID would not get equal
protection, their genotype is an important determinant
in drug utility and protection against CRC
development. In order to make a conclusive exploration
of these potential interactive effects, larger well-
powered studies are needed.

We believe this work would further justify the role of
NFKB1/NFKBIA axis in colon cancer susceptibility.
Further evaluation of the role of rs696 in NFKBIA gene
in other population with an expanded population size
would help to reach a definite conclusion regarding the
role of this polymorphism and may prove its utility as a
CRC screening biomarker.

Acknowledgment

Financial support of Acquired Immunodeficiency
Research Center, Isfahan University of Medical
Sciences, Isfahan, Iran is gratefully acknowledged. We
also appreciate cooperation of all voluntaries
participated in this study.

Conflict of interests

The authors declare that they have no conflict of
interest.

References

1. Cunningham D, Atkin W, Lenz HJ, Lynch HT,
Minsky B, Nordlinger B, et al. Colorectal cancer.
Lancet 2010;375:1030-47.

2. Jemal A, Bray F, Center MM, Ferlay J, Ward E,
Forman D. Global cancer statistics. CA Cancer J Clin
2011;61:69-90.

3. Alwan A. Global status report on
noncommunicable diseases 2010. World Health
Organization; 2011.

4. Etemadi A, Sadjadi A, Semnani S, Nouraie SM,
Khademi H, Bahadori M. Cancer registry in Iran: a
brief overview. Arch Iran Med 2008;11:577-80.

5. Chan AT, Giovannucci EL, Meyerhardt JA,
Scherhhammer ES, Curhan GC, Fuchs CS. Long-term
use of aspirin and nonsteroidal anti-inflammatory
drugs and risk of colorectal cancer. JAMA 2005;294:914-23.

6. Huxley RR, Ansary-Moghaddam A, Clifton P,
Czernichow S, Parr CL, Woodward M. The impact of
dietary and lifestyle risk factors on risk of colorectal
cancer: a quantitative overview of the epidemiological
evidence. Int J Cancer 2009;125:171-80.

7. Alexander C von Roon, George Reese, Julian Teare,
Vasilis Constantinides, Ara W Darzi, Paris P. The risk
of cancer in patients with Crohn's disease. Dis Colon
Rectum 2007;50:839-55.

8. Terzic J, Grivennikov S, Karin E, Karin M.
Inflammation and colon cancer. Gastroenterology
2010;138:2101-14.

9. Perkins ND. The diverse and complex roles of NF-
kappaB subunits in cancer. Nat Rev Cancer 2012;12:121-32.

10. Biswas DK, Cruz AP, Gansberger E, Pardee AB.
Epidermal growth factor-induced nuclear factor kappa
B activation: A major pathway of cell-cycle
progression in estrogen-receptor negative breast cancer
cells. Proc Natl Acad Sci U S A 2000;97:8542-7.

11. Yu HG, Yu LL, Yang Y, Luo HS, Yu JP, Meier JJ,
et al. Increased expression of RelA/nuclear factor-
kappaB protein
correlates with colorectal tumorigenesis. Oncology
2003;65:37-45.

12. Zhang P, Wei Q, Li X, Wang K, Zeng H, Bu H, et
al. A functional insertion/deletion polymorphism in the
promoter region of the NFKB1 gene increases
susceptibility for prostate cancer. Cancer Genet
Cytogenet 2009;191:73-7.

13. Lo SS, Chen JH, Wu CW, Lui WY. Functional
polymorphism of NFKB1 promoter may correlate to
the susceptibility of gastric cancer in aged patients. Surgery 2009;145:280-5.

14. Kim HJ, Kim KW, Yu BP, Chung HY. The effect of age on cyclooxygenase-2 gene expression: NF-κB activation and IκBα degradation. Free Radic Biol Med 2000;28:683-92.

15. Aggarwal BB, Takada Y, Shishodia S, Gutierrez AM, Oommen OV, Ichikawa H, et al. Nuclear transcription factor NF-kappa B: role in biology and medicine. Indian J Exp Biol 2004;42:341-53.

16. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281-97.

17. Carleton M, Cleary MA, Linsley PS. MicroRNAs and cell cycle regulation. Cell Cycle 2007;6:2127-32.

18. Cho WC. MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy. Int J Biochem Cell Biol 2010;42:1273-81.

19. Manikandan M, Munirajan AK. Single nucleotide polymorphisms in microRNA binding sites of oncogenes: implications in cancer and pharmacogenomics. Omics 2014;18:142-54.

20. Song S, Chen D, Lu J, Liao J, Luo Y, Yang Z, et al. NFκB1 and NFκBIA polymorphisms are associated with increased risk for sporadic colorectal cancer in a southern Chinese population. PLoS One 2011;6:e21726.

21. Zhang GL, Zou YF, Feng XL, Shi HJ, Du XF, Shao MH, et al. Association of the NFKBIA gene polymorphisms with susceptibility to autoimmune and inflammatory diseases: a meta-analysis. Inflamm Res 2011;60:11-8.

22. Liu Y, Qiu F, Yang L, Yang R, Yang X, Huang D, et al. Polymorphisms of NFκB1 and IκBα and Their Synergistic Effect on Nasopharyngeal Carcinoma Susceptibility. Biomed Res Int 2015;2015:362542.

23. Gao J, Pfeifer D, He LJ, Qiao F, Zhang Z, Arbman G, et al. Association of NFKBIA polymorphism with colorectal cancer risk and prognosis in Swedish and Chinese populations. Scand J Gastroenterol 2007;42:345-50.

24. Huang D, Yang L, Liu Y, Zhou Y, Guo Y, Pan M, et al. Functional polymorphisms in NFκB1/IκBα predict risks of chronic obstructive pulmonary disease and lung cancer in Chinese. Hum Genet 2013;132:451-60.

25. Umar M, Upadhyay R, Kumar S, Ghoshal UC, Mittal B. Association of common polymorphisms in TNFA, NFKB1 and NFKBIA with risk and prognosis of esophageal squamous cell carcinoma. PLoS One 2013;8:e81999.

26. Osborne J, Lake A, Alexander FE, Taylor G-M, Jarrett RF. Germline mutations and polymorphisms in the NFKBIA gene in Hodgkin lymphoma. Int J Cancer 2005;116:646-51.

27. Han X, Zhang Jj, Yao N, wang G, Mei J, Li B, et al. Polymorphisms in NFKB1 and NFKBIA genes modulate the risk of developing prostate cancer among Han Chinese. Med Sci Monit 2015;21:1707.

28. Oltulu YM, Coskunpinar E, Ozkan G, Aynaci E, Yildiz P, Isbir T, et al. Investigation of NF-κB1 and NF-κBIA gene polymorphism in non-small cell lung cancer. Biomed Res Int 2014;2014:530381.

29. Pallavi S, Anoop K, Showket H, Alo N, Mausumi B. NFKB1/NFKBIA polymorphisms are associated with the progression of cervical carcinoma in HPV-infected postmenopausal women from rural area. Tumor Biol 2015;36:6265-76.

30. Yenmis G, Oner T, Cam C, Koc A, Kucuk OS, Yakicier MC, et al. Association of NFKB1 and NFKBIA polymorphisms in relation to susceptibility of Behçet’s disease. Scand J Immunol 2015;81:81-6.

31. Curran JE, Weinstein SR, Griffiths LR. Polymorphic variants of NFKB1 and its inhibitory protein NFKBIA, and their involvement in sporadic breast cancer. Cancer Lett 2002;188:103-7.

32. Marnett LJ. Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res 1992;52:5575-89.

33. Giardiello F, Offerhaus G, DuBois R. The role of nonsteroidal anti-inflammatory drugs in colorectal cancer prevention. Eur J Cancer 1995;31:1071-6.